[{"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-001", "question": "A 34-year-old woman presents with 6 months of progressive bilateral hand weakness and numbness. She has a 15-year history of systemic lupus erythematosus treated with hydroxychloroquine and low-dose prednisone. Examination reveals symmetric weakness of finger abduction and adduction bilaterally, decreased sensation to pinprick over the ulnar aspect of both hands, and absent ulnar deep tendon reflexes. Nerve conduction studies show reduced compound muscle action potential amplitudes in bilateral ulnar nerves with conduction block at the elbow, prolonged distal motor latencies, and temporal dispersion. Anti-ganglioside antibodies are negative. CSF shows protein 85 mg/dL with 2 WBCs. Which of the following is the most likely diagnosis?", "options": ["Multifocal motor neuropathy with conduction block", "Chronic inflammatory demyelinating polyneuropathy", "Lupus-associated mononeuritis multiplex", "Lewis-Sumner syndrome", "Hereditary neuropathy with liability to pressure palsies"], "answer": "D", "answer_index": 3, "explanation": "Lewis-Sumner syndrome (multifocal acquired demyelinating sensory and motor neuropathy, MADSAM) is characterized by asymmetric sensorimotor involvement with demyelinating features including conduction block, distinguishing it from multifocal motor neuropathy (purely motor, anti-GM1 positive) and CIDP (symmetric). The presence of sensory symptoms and signs excludes MMN. Lupus mononeuritis multiplex typically shows axonal rather than demyelinating features. HNPP would show conduction abnormalities at typical compression sites without temporal dispersion.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: K. Verdict on keyed answer: Miskeyed. Key stem clues that drive (or fail to drive) a unique best answer: Progressive bilateral symmetric hand weakness and numbness, symmetric finger ab/adduction weakness, bilateral ulnar sensory loss, absent ulnar DTRs, NCS showing bilateral ulnar demyelination with conduction block at elbows, prolonged DML, temporal dispersion, negative anti-ganglioside Abs, CSF protein 85 mg/dL with 2 WBCs, and SLE history. These support a symmetric sensory-motor demyelinating polyneuropathy, pointing to CIDP (B) as the unique best answer due to symmetry, demyelinating features, and elevated CSF protein without pleocytosis. Main logical issue(s): The keyed answer (D, Lewis-Sumner syndrome) requires asymmetric involvement per standard definitions and the provided rationale, but the stem explicitly describes symmetric findings, making D indefensible and B the clear single best option without contradictions or underspecification. Main medical accuracy issue(s): Keyed answer inconsistent with current mainstream standards; symmetric presentation aligns with classic CIDP, not the typically asymmetric Lewis-Sumner (MADSAM) variant; rationale accurately distinguishes but mismatches the stem's symmetry, potentially misleading learners on diagnostic criteria. Minimal fix: Revise stem to describe 'asymmetric weakness' instead of 'symmetric' to align with keyed answer D and maintain logical validity.\",\n  \"medical_accuracy_score\": 2,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"K\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K. Verdict on keyed answer: Miskeyed. Key stem clues that drive (or fail to drive) a unique best answer: Progressive bilateral symmetric hand weakness and numbness, symmetric finger ab/adduction weakness, bilateral ulnar sensory loss, absent ulnar DTRs, NCS showing bilateral ulnar demyelination with conduction block at elbows, prolonged DML, temporal dispersion, negative anti-ganglioside Abs, CSF protein 85 mg/dL with 2 WBCs, and SLE history. These support a symmetric sensory-motor demyelinating polyneuropathy, pointing to CIDP (B) as the unique best answer due to symmetry, demyelinating features, and elevated CSF protein without pleocytosis. Main logical issue(s): The keyed answer (D, Lewis-Sumner syndrome) requires asymmetric involvement per standard definitions and the provided rationale, but the stem explicitly describes symmetric findings, making D indefensible and B the clear single best option without contradictions or underspecification. Main medical accuracy issue(s): Keyed answer inconsistent with current mainstream standards; symmetric presentation aligns with classic CIDP, not the typically asymmetric Lewis-Sumner (MADSAM) variant; rationale accurately distinguishes but mismatches the stem's symmetry, potentially misleading learners on diagnostic criteria. Minimal fix: Revise stem to describe 'asymmetric weakness' instead of 'symmetric' to align with keyed answer D and maintain logical validity.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-002", "question": "A 28-year-old woman at 32 weeks gestation presents with sudden onset severe headache, visual disturbances, and confusion. Blood pressure is 178/112 mmHg. Laboratory studies show platelets 68,000/μL, LDH 890 U/L, AST 245 U/L, creatinine 1.8 mg/dL, and peripheral smear with schistocytes. She receives magnesium sulfate and labetalol. Emergent cesarean delivery is performed. Postpartum day 3, despite delivery, her platelet count drops to 42,000/μL, creatinine rises to 2.9 mg/dL, and she develops new neurological symptoms. ADAMTS13 activity returns at 58%. Which additional finding would most strongly support initiating eculizumab therapy?", "options": ["Positive direct antiglobulin test", "Complement factor H mutation on genetic testing", "Elevated soluble fms-like tyrosine kinase-1 levels", "Low C3 with normal C4 levels", "Presence of anti-phospholipid antibodies"], "answer": "B", "answer_index": 1, "explanation": "This presentation of postpartum thrombotic microangiopathy not resolving after delivery with ADAMTS13 >10% suggests complement-mediated TMA (atypical HUS) rather than TTP or HELLP syndrome. Complement factor H mutation confirms complement dysregulation and strongly supports eculizumab (C5 inhibitor) therapy. Low C3 with normal C4 suggests alternative pathway activation but is nonspecific. Elevated sFlt-1 would suggest ongoing preeclampsia-related pathology. Positive DAT would suggest Evans syndrome, and anti-phospholipid antibodies suggest catastrophic APS, both requiring different management.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: Postpartum thrombotic microangiopathy (TMA) with persistent thrombocytopenia (42,000/μL), rising creatinine (2.9 mg/dL), new neurological symptoms despite delivery, and ADAMTS13 activity at 58% (ruling out TTP, as >10% is inconsistent with severe deficiency). These point to complement-mediated TMA like atypical hemolytic uremic syndrome (aHUS), where eculizumab (C5 inhibitor) is indicated if complement dysregulation is confirmed.\\nMain logical issue(s), if any: None; the stem provides sufficient details to discriminate options without contradictions or underspecification, supporting B as uniquely best (CFH mutation directly confirms genetic aHUS etiology warranting eculizumab).\\nMain medical accuracy issue(s), if any: None; aligns with current guidelines (e.g., KDIGO for aHUS management), where CFH mutations are a common cause of complement dysregulation, and eculizumab is first-line for confirmed cases. ADAMTS13 >10% appropriately excludes TTP; alternatives like low C3 (nonspecific) or elevated sFlt-1 (preeclampsia-related) are correctly less supportive.\\nMinimal fix: No fix needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: Postpartum thrombotic microangiopathy (TMA) with persistent thrombocytopenia (42,000/μL), rising creatinine (2.9 mg/dL), new neurological symptoms despite delivery, and ADAMTS13 activity at 58% (ruling out TTP, as >10% is inconsistent with severe deficiency). These point to complement-mediated TMA like atypical hemolytic uremic syndrome (aHUS), where eculizumab (C5 inhibitor) is indicated if complement dysregulation is confirmed.\nMain logical issue(s), if any: None; the stem provides sufficient details to discriminate options without contradictions or underspecification, supporting B as uniquely best (CFH mutation directly confirms genetic aHUS etiology warranting eculizumab).\nMain medical accuracy issue(s), if any: None; aligns with current guidelines (e.g., KDIGO for aHUS management), where CFH mutations are a common cause of complement dysregulation, and eculizumab is first-line for confirmed cases. ADAMTS13 >10% appropriately excludes TTP; alternatives like low C3 (nonspecific) or elevated sFlt-1 (preeclampsia-related) are correctly less supportive.\nMinimal fix: No fix needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-003", "question": "A 52-year-old man with hypertrophic cardiomyopathy and an ICD presents with recurrent appropriate shocks for ventricular tachycardia despite maximum tolerated doses of metoprolol and disopyramide. Echocardiogram shows septal thickness of 22 mm, LVOT gradient of 85 mmHg at rest, and moderate mitral regurgitation with systolic anterior motion. Cardiac MRI demonstrates 18% late gadolinium enhancement predominantly in the septum. Coronary angiography is normal. Which intervention is most likely to reduce his arrhythmia burden?", "options": ["Alcohol septal ablation", "Surgical septal myectomy with mitral valve repair", "Catheter ablation of ventricular tachycardia", "Addition of amiodarone to current regimen", "Cardiac transplantation evaluation"], "answer": "B", "answer_index": 1, "explanation": "In HCM patients with significant LVOT obstruction, extensive LGE (>15%), and recurrent VT, surgical myectomy is preferred over alcohol septal ablation because ASA creates additional scar that may be proarrhythmic. Myectomy reduces obstruction and allows concomitant mitral valve repair for SAM-related MR. The extensive LGE indicates high arrhythmic substrate burden. VT ablation addresses the arrhythmia but not the underlying obstruction driving symptoms. Amiodarone adds toxicity risk without addressing mechanism. Transplant is premature given available surgical options.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include recurrent VT shocks despite maximal medical therapy, significant LVOT obstruction (85 mmHg gradient), septal hypertrophy (22 mm), moderate MR with SAM, and extensive septal LGE (18%), with normal coronaries. These point to obstructive HCM with high arrhythmic risk from fibrosis and dynamic obstruction, making surgical intervention to relieve obstruction and address SAM/MR optimal for reducing arrhythmia burden. Main logical issue(s): none; the stem provides sufficient discriminating details (e.g., resting gradient, LGE extent, SAM) to favor myectomy over alternatives without contradictions or underspecification. Main medical accuracy issue(s): none; aligns with AHA/ACC guidelines preferring surgical myectomy in symptomatic obstructive HCM with extensive fibrosis, as it reduces gradient, allows mitral repair, and avoids proarrhythmic scar from ASA. VT ablation treats arrhythmia but not substrate; amiodarone adds risks without mechanistic benefit; transplant is not first-line. Minimal fix: none needed, as item is unambiguous and accurate. The clinical problem asks for the intervention most likely to reduce arrhythmia in refractory obstructive HCM. Discriminating findings: positive (obstruction, SAM, MR, LGE>15%, VT shocks); negative (normal coronaries, max meds). Implied: myectomy as definitive therapy. Keyed B fits without assumptions. Alternatives: A worse due to scar risk; C ignores obstruction; D toxic; E premature.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include recurrent VT shocks despite maximal medical therapy, significant LVOT obstruction (85 mmHg gradient), septal hypertrophy (22 mm), moderate MR with SAM, and extensive septal LGE (18%), with normal coronaries. These point to obstructive HCM with high arrhythmic risk from fibrosis and dynamic obstruction, making surgical intervention to relieve obstruction and address SAM/MR optimal for reducing arrhythmia burden. Main logical issue(s): none; the stem provides sufficient discriminating details (e.g., resting gradient, LGE extent, SAM) to favor myectomy over alternatives without contradictions or underspecification. Main medical accuracy issue(s): none; aligns with AHA/ACC guidelines preferring surgical myectomy in symptomatic obstructive HCM with extensive fibrosis, as it reduces gradient, allows mitral repair, and avoids proarrhythmic scar from ASA. VT ablation treats arrhythmia but not substrate; amiodarone adds risks without mechanistic benefit; transplant is not first-line. Minimal fix: none needed, as item is unambiguous and accurate. The clinical problem asks for the intervention most likely to reduce arrhythmia in refractory obstructive HCM. Discriminating findings: positive (obstruction, SAM, MR, LGE>15%, VT shocks); negative (normal coronaries, max meds). Implied: myectomy as definitive therapy. Keyed B fits without assumptions. Alternatives: A worse due to scar risk; C ignores obstruction; D toxic; E premature.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-004", "question": "A 45-year-old woman with dermatomyositis diagnosed 8 months ago presents with progressive dyspnea. She was initially treated with high-dose prednisone and azathioprine with improvement in proximal muscle weakness. CT chest shows new ground-glass opacities with peripheral consolidation in lower lobes. Pulmonary function tests reveal FVC 58% predicted, DLCO 42% predicted. Bronchoalveolar lavage shows 35% lymphocytes. She tests positive for anti-MDA5 antibodies. Which treatment approach offers the best chance of halting disease progression?", "options": ["Increase prednisone and add mycophenolate mofetil", "Triple therapy with high-dose glucocorticoids, calcineurin inhibitor, and cyclophosphamide", "Rituximab with continued azathioprine", "Nintedanib with continued current immunosuppression", "Plasma exchange followed by IVIG maintenance"], "answer": "B", "answer_index": 1, "explanation": "Anti-MDA5 dermatomyositis-associated rapidly progressive interstitial lung disease carries high mortality and requires aggressive upfront combination immunosuppression. Japanese and international experience supports triple therapy with high-dose corticosteroids, a calcineurin inhibitor (tacrolimus or cyclosporine), and cyclophosphamide as the most effective approach for halting progression. Single-agent additions or rituximab have shown inferior outcomes in this specific antibody subset. Nintedanib is antifibrotic, not immunosuppressive. Plasma exchange lacks evidence in this context.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: 45-year-old woman with dermatomyositis, progressive dyspnea despite initial treatment with prednisone and azathioprine, new CT ground-glass opacities with peripheral consolidation in lower lobes, reduced FVC (58%) and DLCO (42%), BAL with 35% lymphocytes, and positive anti-MDA5 antibodies—these point to rapidly progressive interstitial lung disease (RP-ILD) in anti-MDA5 dermatomyositis, requiring aggressive immunosuppression to halt progression.\\nMain logical issue(s), if any: None; the stem provides sufficient discriminating details (antibody status, imaging, PFTs, BAL) to identify triple therapy as the single best option without contradictions or underspecification.\\nMain medical accuracy issue(s), if any: None; aligns with current evidence from Japanese and international cohorts supporting upfront triple therapy (high-dose glucocorticoids, calcineurin inhibitor, cyclophosphamide) for anti-MDA5 RP-ILD due to high mortality; alternatives like rituximab or nintedanib are less effective or inappropriate as primary therapy per guidelines.\\nMinimal fix: No edit necessary; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: 45-year-old woman with dermatomyositis, progressive dyspnea despite initial treatment with prednisone and azathioprine, new CT ground-glass opacities with peripheral consolidation in lower lobes, reduced FVC (58%) and DLCO (42%), BAL with 35% lymphocytes, and positive anti-MDA5 antibodies—these point to rapidly progressive interstitial lung disease (RP-ILD) in anti-MDA5 dermatomyositis, requiring aggressive immunosuppression to halt progression.\nMain logical issue(s), if any: None; the stem provides sufficient discriminating details (antibody status, imaging, PFTs, BAL) to identify triple therapy as the single best option without contradictions or underspecification.\nMain medical accuracy issue(s), if any: None; aligns with current evidence from Japanese and international cohorts supporting upfront triple therapy (high-dose glucocorticoids, calcineurin inhibitor, cyclophosphamide) for anti-MDA5 RP-ILD due to high mortality; alternatives like rituximab or nintedanib are less effective or inappropriate as primary therapy per guidelines.\nMinimal fix: No edit necessary; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-005", "question": "A 38-year-old man from Cambodia presents with 3 weeks of fever, headache, and altered mental status. CSF analysis shows opening pressure 32 cm H2O, WBC 180/μL (90% lymphocytes), protein 120 mg/dL, glucose 28 mg/dL (serum 110 mg/dL). India ink preparation shows encapsulated yeast. Cryptococcal antigen titer is 1:2048 in CSF. HIV testing is positive with CD4 count of 35 cells/μL. He is started on liposomal amphotericin B and flucytosine with daily therapeutic lumbar punctures. On day 10, repeat lumbar puncture shows opening pressure 38 cm H2O, CSF WBC 420/μL (85% lymphocytes), protein 180 mg/dL, and cryptococcal antigen titer 1:1024. He has worsening headache and new sixth nerve palsy. What is the most appropriate next step?", "options": ["Add dexamethasone for paradoxical immune reconstitution inflammatory syndrome", "Switch to high-dose fluconazole for amphotericin resistance", "Place a ventriculoperitoneal shunt for refractory elevated intracranial pressure", "Continue current antifungal therapy with more aggressive CSF drainage", "Initiate antiretroviral therapy immediately to improve immune function"], "answer": "D", "answer_index": 3, "explanation": "The rising CSF pleocytosis with persistent elevated opening pressure despite treatment represents ongoing cryptococcal meningitis with inadequate pressure management rather than treatment failure or IRIS (patient not yet on ART). The antigen titer is decreasing appropriately. Management requires more aggressive CSF drainage-either more frequent LPs or temporary lumbar drain placement. Corticosteroids are contraindicated in cryptococcal meningitis (increased mortality in COAT trial). VPS is reserved for truly refractory cases after optimizing medical management. Early ART initiation increases IRIS risk and mortality when started before 4-6 weeks of antifungal therapy.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include decreasing cryptococcal antigen titer (1:2048 to 1:1024) indicating antifungal response, rising opening pressure (32 to 38 cm H2O), increasing CSF WBC (180 to 420/μL) and protein (120 to 180 mg/dL), worsening headache, and new sixth nerve palsy suggesting persistent elevated ICP despite daily LPs; HIV+ with low CD4 but no ART initiated, ruling out typical IRIS. Main logical issue(s): None; the vignette provides sufficient details to discriminate options without contradictions or underspecification, supporting D as uniquely best by emphasizing inadequate ICP management over resistance, IRIS, shunt, or premature ART. Main medical accuracy issue(s): None; aligns with IDSA guidelines for HIV-associated cryptococcal meningitis—induction with liposomal amphotericin B and flucytosine, aggressive CSF drainage for ICP >25 cm H2O, delayed ART (4-6 weeks) to avoid IRIS, and avoidance of corticosteroids due to increased mortality (e.g., COAT trial). Antigen decline confirms treatment efficacy, not resistance. Minimal fix: None needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include decreasing cryptococcal antigen titer (1:2048 to 1:1024) indicating antifungal response, rising opening pressure (32 to 38 cm H2O), increasing CSF WBC (180 to 420/μL) and protein (120 to 180 mg/dL), worsening headache, and new sixth nerve palsy suggesting persistent elevated ICP despite daily LPs; HIV+ with low CD4 but no ART initiated, ruling out typical IRIS. Main logical issue(s): None; the vignette provides sufficient details to discriminate options without contradictions or underspecification, supporting D as uniquely best by emphasizing inadequate ICP management over resistance, IRIS, shunt, or premature ART. Main medical accuracy issue(s): None; aligns with IDSA guidelines for HIV-associated cryptococcal meningitis—induction with liposomal amphotericin B and flucytosine, aggressive CSF drainage for ICP >25 cm H2O, delayed ART (4-6 weeks) to avoid IRIS, and avoidance of corticosteroids due to increased mortality (e.g., COAT trial). Antigen decline confirms treatment efficacy, not resistance. Minimal fix: None needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-006", "question": "A 67-year-old woman with longstanding rheumatoid arthritis on methotrexate and adalimumab develops progressive cognitive decline over 4 months. MRI brain shows multifocal white matter lesions without enhancement or mass effect. CSF shows 8 WBCs (all lymphocytes), protein 62 mg/dL, and negative routine cultures. JC virus PCR in CSF is positive with 850 copies/mL. Adalimumab is discontinued. Three weeks later, she develops new right hemiparesis and worsening confusion. Repeat MRI shows enlargement of lesions with new peripheral enhancement and edema. CSF now shows 45 WBCs (predominantly lymphocytes). What is the most appropriate management?", "options": ["Restart adalimumab to suppress destructive inflammation", "Initiate high-dose corticosteroids", "Begin cidofovir and cytarabine combination therapy", "Administer pembrolizumab to enhance JC virus clearance", "Perform brain biopsy to exclude CNS lymphoma"], "answer": "B", "answer_index": 1, "explanation": "This patient has developed immune reconstitution inflammatory syndrome (IRIS) following discontinuation of immunosuppression in the setting of PML. The new enhancement, edema, and increased CSF pleocytosis after stopping adalimumab are classic for PML-IRIS. High-dose corticosteroids are indicated to reduce the inflammatory response that, while representing immune recovery, can cause significant neurological damage. Restarting immunosuppression would be counterproductive. Cidofovir/cytarabine lack efficacy in PML. Pembrolizumab is used in refractory PML without immune reconstitution, not IRIS. Biopsy is unnecessary given confirmed JC virus and classic IRIS presentation.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: 67-year-old woman with RA on methotrexate and adalimumab presents with progressive cognitive decline; MRI shows multifocal white matter lesions without enhancement; CSF reveals mild lymphocytosis, elevated protein, positive JC virus PCR (850 copies/mL), confirming PML. Adalimumab discontinuation followed by new hemiparesis, worsening confusion, MRI with lesion enlargement, peripheral enhancement, edema, and increased CSF pleocytosis (45 WBCs, lymphocytic) indicate PML-IRIS due to immune reconstitution.\\nMain logical issue(s), if any: None; the vignette provides sufficient discriminating findings (initial PML features transitioning to inflammatory changes post-immunosuppression reduction) to support B as the unique best management without contradictions or underspecification.\\nMain medical accuracy issue(s), if any: None; aligns with current standards for PML-IRIS management, where high-dose corticosteroids mitigate destructive inflammation during immune recovery. Alternatives are appropriately inferior: restarting adalimumab (A) worsens immunosuppression; cidofovir/cytarabine (C) lack efficacy; pembrolizumab (D) suits refractory PML sans IRIS; biopsy (E) unnecessary with confirmed JC virus and classic presentation.\\nMinimal fix: None required; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: 67-year-old woman with RA on methotrexate and adalimumab presents with progressive cognitive decline; MRI shows multifocal white matter lesions without enhancement; CSF reveals mild lymphocytosis, elevated protein, positive JC virus PCR (850 copies/mL), confirming PML. Adalimumab discontinuation followed by new hemiparesis, worsening confusion, MRI with lesion enlargement, peripheral enhancement, edema, and increased CSF pleocytosis (45 WBCs, lymphocytic) indicate PML-IRIS due to immune reconstitution.\nMain logical issue(s), if any: None; the vignette provides sufficient discriminating findings (initial PML features transitioning to inflammatory changes post-immunosuppression reduction) to support B as the unique best management without contradictions or underspecification.\nMain medical accuracy issue(s), if any: None; aligns with current standards for PML-IRIS management, where high-dose corticosteroids mitigate destructive inflammation during immune recovery. Alternatives are appropriately inferior: restarting adalimumab (A) worsens immunosuppression; cidofovir/cytarabine (C) lack efficacy; pembrolizumab (D) suits refractory PML sans IRIS; biopsy (E) unnecessary with confirmed JC virus and classic presentation.\nMinimal fix: None required; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-007", "question": "A 29-year-old woman presents with 2 years of recurrent oral ulcers, genital ulcers, and bilateral anterior uveitis. She now develops sudden painless vision loss in her right eye. Examination reveals visual acuity of hand motion OD and 20/25 OS. Fundoscopy of the right eye shows diffuse retinal whitening with cherry-red spot and box-carring in retinal arterioles. Fluorescein angiography confirms central retinal artery occlusion. HLA-B51 is positive. Pathergy test is negative. What is the most appropriate immediate intervention to prevent contralateral involvement?", "options": ["High-dose intravenous methylprednisolone alone", "Infliximab infusion", "Combination of high-dose corticosteroids with cyclosporine", "Combination of high-dose corticosteroids with infliximab or adalimumab", "Anterior chamber paracentesis with ocular massage"], "answer": "D", "answer_index": 3, "explanation": "This patient has Behçet disease with ocular involvement including the devastating complication of retinal artery occlusion from retinal vasculitis. Immediate aggressive immunosuppression is critical to prevent bilateral blindness. Current evidence supports combination therapy with high-dose corticosteroids plus a TNF-alpha inhibitor (infliximab or adalimumab) as the most effective approach for severe ocular Behçet. Corticosteroids alone or with cyclosporine are insufficient for this severity. Anterior chamber paracentesis addresses embolic CRAO, not inflammatory vasculitic occlusion. The goal is preventing contralateral involvement through rapid inflammation control.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include recurrent oral and genital ulcers, bilateral anterior uveitis, HLA-B51 positivity (supporting Behçet disease), and acute right-eye CRAO with fundoscopic findings of retinal whitening, cherry-red spot, and box-carring, indicating vasculitic occlusion rather than embolic. The question asks for immediate intervention to prevent contralateral involvement in severe ocular Behçet. These clues imply the need for aggressive systemic immunosuppression targeting inflammation to avert bilateral blindness. Option D (high-dose corticosteroids with infliximab or adalimumab) aligns with current guidelines for rapid control in severe cases. Main logical issue(s): none; the stem provides sufficient discriminating details without contradictions or underspecification, allowing D as the unique best. Alternatives are inferior: A lacks adjunctive therapy; B is monotherapy; C uses cyclosporine, which is less effective for vasculitic complications; E addresses embolic CRAO, mismatched to the inflammatory etiology. Main medical accuracy issue(s): none; consistent with mainstream standards (e.g., EULAR recommendations) favoring TNF inhibitors plus steroids for sight-threatening Behçet uveitis. Minimal fix: none needed, as the item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include recurrent oral and genital ulcers, bilateral anterior uveitis, HLA-B51 positivity (supporting Behçet disease), and acute right-eye CRAO with fundoscopic findings of retinal whitening, cherry-red spot, and box-carring, indicating vasculitic occlusion rather than embolic. The question asks for immediate intervention to prevent contralateral involvement in severe ocular Behçet. These clues imply the need for aggressive systemic immunosuppression targeting inflammation to avert bilateral blindness. Option D (high-dose corticosteroids with infliximab or adalimumab) aligns with current guidelines for rapid control in severe cases. Main logical issue(s): none; the stem provides sufficient discriminating details without contradictions or underspecification, allowing D as the unique best. Alternatives are inferior: A lacks adjunctive therapy; B is monotherapy; C uses cyclosporine, which is less effective for vasculitic complications; E addresses embolic CRAO, mismatched to the inflammatory etiology. Main medical accuracy issue(s): none; consistent with mainstream standards (e.g., EULAR recommendations) favoring TNF inhibitors plus steroids for sight-threatening Behçet uveitis. Minimal fix: none needed, as the item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-008", "question": "A 41-year-old man with no significant medical history presents with 6 weeks of progressive bilateral lower extremity weakness and paresthesias. He reports a diarrheal illness 8 weeks ago. Examination shows 3/5 strength in hip flexors, 4/5 in knee extensors, 4-/5 in ankle dorsiflexors bilaterally, absent deep tendon reflexes, and decreased vibration sense to the knees. Nerve conduction studies show reduced CMAP amplitudes with normal conduction velocities and no conduction block. Needle EMG shows active denervation in distal leg muscles. CSF protein is 95 mg/dL with 1 WBC. Anti-GM1 IgG antibodies are strongly positive. Despite 5 days of IVIG, he continues to worsen with new respiratory compromise requiring intubation. What is the next best step in management?", "options": ["Repeat IVIG course immediately", "Initiate plasma exchange", "Add high-dose intravenous methylprednisolone", "Begin eculizumab therapy", "Administer second IVIG course after 4-week interval"], "answer": "B", "answer_index": 1, "explanation": "This patient has acute motor axonal neuropathy (AMAN) variant of Guillain-Barré syndrome, evidenced by pure motor axonal pattern on NCS, anti-GM1 antibodies, and preceding Campylobacter-like illness. When patients fail to respond to initial IVIG and continue deteriorating, plasma exchange is the appropriate next step as it works through a different mechanism (antibody removal vs. immunomodulation). The treatments are not synergistic when given together but can be used sequentially. Corticosteroids are ineffective in GBS. Eculizumab has shown promise in refractory cases but is not yet standard of care. Waiting 4 weeks for repeat IVIG is inappropriate in a deteriorating patient.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include progressive weakness post-diarrheal illness, axonal NCS pattern with reduced CMAP/normal velocities/no block, positive anti-GM1 IgG, elevated CSF protein with acellularity, and deterioration with respiratory failure despite IVIG, pointing to refractory AMAN variant of GBS requiring alternative therapy. Main logical issues: None; the vignette provides sufficient discriminating details (e.g., axonal features, antibody positivity, IVIG failure with acute worsening) to identify plasma exchange as the single best next step without contradictions or underspecification. Main medical accuracy issues: None; aligns with current guidelines (e.g., IVIG and PLEX as equivalent first-line for GBS, sequential use in non-responders; steroids ineffective; eculizumab investigational). The clinical problem asks for next management in IVIG-refractory deteriorating GBS. Key findings: post-infectious axonal neuropathy, anti-GM1 positive, high CSF protein, ongoing decline to intubation. Implied diagnosis: AMAN-GBS. Keyed answer B fits as PLEX removes antibodies differently from IVIG. Alternatives: A lacks evidence for immediate repeat; C ineffective per evidence; D not standard; E delays care inappropriately. Minimal fix: None required; item is unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include progressive weakness post-diarrheal illness, axonal NCS pattern with reduced CMAP/normal velocities/no block, positive anti-GM1 IgG, elevated CSF protein with acellularity, and deterioration with respiratory failure despite IVIG, pointing to refractory AMAN variant of GBS requiring alternative therapy. Main logical issues: None; the vignette provides sufficient discriminating details (e.g., axonal features, antibody positivity, IVIG failure with acute worsening) to identify plasma exchange as the single best next step without contradictions or underspecification. Main medical accuracy issues: None; aligns with current guidelines (e.g., IVIG and PLEX as equivalent first-line for GBS, sequential use in non-responders; steroids ineffective; eculizumab investigational). The clinical problem asks for next management in IVIG-refractory deteriorating GBS. Key findings: post-infectious axonal neuropathy, anti-GM1 positive, high CSF protein, ongoing decline to intubation. Implied diagnosis: AMAN-GBS. Keyed answer B fits as PLEX removes antibodies differently from IVIG. Alternatives: A lacks evidence for immediate repeat; C ineffective per evidence; D not standard; E delays care inappropriately. Minimal fix: None required; item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-009", "question": "A 55-year-old woman with mechanical mitral valve replacement on warfarin presents with acute onset aphasia and right hemiplegia. Symptoms began 90 minutes ago. CT head shows no hemorrhage. CT angiography reveals left M1 occlusion. INR is 2.8. CT perfusion shows large penumbra with small core infarct (ASPECTS 8). Blood pressure is 165/95 mmHg. What is the most appropriate next step?", "options": ["Administer IV alteplase followed by endovascular thrombectomy", "Proceed directly to endovascular thrombectomy without IV thrombolysis", "Reverse anticoagulation with 4-factor PCC then administer IV alteplase", "Administer idarucizumab followed by IV alteplase", "Medical management only with blood pressure optimization"], "answer": "B", "answer_index": 1, "explanation": "In patients with acute ischemic stroke on therapeutic anticoagulation (INR >1.7), IV thrombolysis is contraindicated due to bleeding risk. However, mechanical thrombectomy is not contraindicated and should be pursued emergently in patients with large vessel occlusion and favorable perfusion imaging (large penumbra, small core). Reversing anticoagulation to give tPA adds delay and the combination increases bleeding risk. Idarucizumab reverses dabigatran, not warfarin. Medical management alone would result in completed large territory infarction given the M1 occlusion. Direct thrombectomy offers the best risk-benefit profile.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 55-year-old with mechanical mitral valve on warfarin (INR 2.8, therapeutic), acute ischemic stroke symptoms (aphasia, hemiplegia) onset 90 minutes ago, CT head no hemorrhage, CTA shows left M1 occlusion, CT perfusion large penumbra with small core (ASPECTS 8), BP 165/95. These support acute LVO stroke ineligible for IV thrombolysis due to anticoagulation but eligible for thrombectomy. Main logical issue(s): None; stem provides sufficient details for discrimination without contradictions or underspecification, allowing unique best answer (B) over alternatives. Main medical accuracy issue(s): None; aligns with AHA/ASA guidelines contraindicating IV alteplase for INR >1.7 in anticoagulated patients, recommending direct thrombectomy for LVO with favorable imaging; idarucizumab is correctly irrelevant for warfarin; reversal for tPA not standard due to risks/delays. Minimal fix: None required, but adding explicit time window confirmation (e.g., <6 hours for thrombectomy) could enhance clarity, though already implied by urgency and imaging.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 55-year-old with mechanical mitral valve on warfarin (INR 2.8, therapeutic), acute ischemic stroke symptoms (aphasia, hemiplegia) onset 90 minutes ago, CT head no hemorrhage, CTA shows left M1 occlusion, CT perfusion large penumbra with small core (ASPECTS 8), BP 165/95. These support acute LVO stroke ineligible for IV thrombolysis due to anticoagulation but eligible for thrombectomy. Main logical issue(s): None; stem provides sufficient details for discrimination without contradictions or underspecification, allowing unique best answer (B) over alternatives. Main medical accuracy issue(s): None; aligns with AHA/ASA guidelines contraindicating IV alteplase for INR >1.7 in anticoagulated patients, recommending direct thrombectomy for LVO with favorable imaging; idarucizumab is correctly irrelevant for warfarin; reversal for tPA not standard due to risks/delays. Minimal fix: None required, but adding explicit time window confirmation (e.g., <6 hours for thrombectomy) could enhance clarity, though already implied by urgency and imaging.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed124-010", "question": "A 33-year-old woman with no prior cardiac history presents with progressive exertional dyspnea over 3 months. She delivered her third child 5 months ago. Echocardiogram shows left ventricular ejection fraction of 25%, LV end-diastolic diameter of 62 mm, moderate functional mitral regurgitation, and no thrombus. BNP is 1,850 pg/mL. She is started on guideline-directed medical therapy including sacubitril-valsartan, carvedilol, spironolactone, and dapagliflozin. Genetic testing reveals a truncating variant in the TTN gene. At 6-month follow-up, LVEF has improved to 40% but remains below normal. Which factor most strongly predicts her likelihood of complete LV recovery?", "options": ["Absence of late gadolinium enhancement on cardiac MRI", "Normalization of BNP levels", "Presence of the TTN truncating variant", "Baseline LVEF above 30%", "Multiparity status"], "answer": "A", "answer_index": 0, "explanation": "In peripartum cardiomyopathy, the absence of late gadolinium enhancement (LGE) on cardiac MRI is the strongest predictor of complete LV recovery, indicating absence of irreversible myocardial fibrosis. TTN truncating variants are actually associated with incomplete recovery and persistent LV dysfunction in PPCM, making option C incorrect. While BNP normalization and higher baseline LVEF are favorable, they are less predictive than LGE status. Multiparity is a risk factor for developing PPCM but does not predict recovery. LGE represents scar that cannot recover regardless of optimal medical therapy.", "generator_model": "claude-opus-4-5-20251101", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include postpartum onset of heart failure (5 months post-delivery), initial LVEF 25% improving to 40% on GDMT, TTN truncating variant, elevated BNP, dilated LV, and moderate MR, consistent with peripartum cardiomyopathy (PPCM). These support evaluating predictors of full LV recovery, where absence of late gadolinium enhancement (LGE) on cardiac MRI is the strongest indicator of reversible injury without fibrosis. The TTN variant predicts poorer recovery, making C incorrect; higher baseline LVEF (hers was 25%, below 30%) is favorable but less predictive than LGE; BNP normalization is positive but secondary; multiparity risks PPCM development but not recovery. No main logical issues; stem allows discrimination of A as uniquely best based on standard PPCM knowledge without contradictions or underspecification. No main medical accuracy issues; aligns with current guidelines (e.g., ESC, AHA) on PPCM predictors, where LGE absence strongly forecasts recovery, TTN variants associate with persistence, and GDMT is appropriate. Minimal fix: No edit necessary; item is unambiguous and accurate as is.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include postpartum onset of heart failure (5 months post-delivery), initial LVEF 25% improving to 40% on GDMT, TTN truncating variant, elevated BNP, dilated LV, and moderate MR, consistent with peripartum cardiomyopathy (PPCM). These support evaluating predictors of full LV recovery, where absence of late gadolinium enhancement (LGE) on cardiac MRI is the strongest indicator of reversible injury without fibrosis. The TTN variant predicts poorer recovery, making C incorrect; higher baseline LVEF (hers was 25%, below 30%) is favorable but less predictive than LGE; BNP normalization is positive but secondary; multiparity risks PPCM development but not recovery. No main logical issues; stem allows discrimination of A as uniquely best based on standard PPCM knowledge without contradictions or underspecification. No main medical accuracy issues; aligns with current guidelines (e.g., ESC, AHA) on PPCM predictors, where LGE absence strongly forecasts recovery, TTN variants associate with persistence, and GDMT is appropriate. Minimal fix: No edit necessary; item is unambiguous and accurate as is.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]